A High-Throughput Amplicon Screen for Somatic UBA1 Variants in Cytopenic and Giant Cell Arteritis Cohorts

Somatic mutations in the gene encoding the major E1


To the Editor
Somatic mutations in the gene encoding the major E1 ubiquitin ligase, UBA1, cause VEXAS (Vacuoles, E1-ligase, X-linked, Auto-inflammatory, Somatic), a late-onset acquired and progressive auto-inflammatory syndrome [1]. Patients with VEXAS are typically male, aged over 60 years with a severe systemic inflammatory disorder, and cytopenia and dysplastic features in their bone marrow [1]. Differential diagnoses for patients subsequently found to have VEXAS include relapsing polychondritis (most frequent diagnosis), Sweet's syndrome, myelodysplastic syndrome (MDS), giant cell arteritis (GCA), and undifferentiated systemic autoinflammatory disease (uSAID).
To date, cases of VEXAS have been identified by sequencing of exon 3 of UBA1, with a particular focus on identifying Methionine-41 (Met41) or splice site mutations [1]. Only 1 amino acid substitution, p.Ser56Phe, has been identified that does not affect Met41, resulting in a temperature-dependent reduction of ubiquitin ligase activity [1]. This finding suggests similar missense variants may exist. The milder phenotype observed in the p.Ser56Phe patient indicated individuals with non-Met41 variants may also have milder disease, for which VEXAS may not be considered.
In this study, we sought to investigate the frequency of VEXAS-associated mutations in patients with confirmed GCA and those with unexplained cytopenia. This would ultimately inform future diagnostic algorithms for VEXAS screening in patients in either of these scenarios. To achieve this, we developed a high-throughput inexpensive assay (for details, please see supplementary material and method section) with which we screened 1667 samples for all described VEXAS-associated UBA1 mutations identified to date. A summary of both cohorts can be found in Table 1. While only male GCA cases were selected, no exclusion criteria were applied to the cytopenia cohort.
The cytopenia cohort screened consisted of 1055 nondiagnostic cases from a large cytopenic cohort (n = 2125), for whom bone marrow DNA was available (for details, please see supplementary methods). A summary of the cohort can be found in Supplementary Table 2. The cohort includes both male and female adult patients (≥ 18 years). All samples were taken with full-informed patient consent for investigation of a suspected hematological disorder, with local ethical committee approval (16/NE/0105).
The GCA cohort screened consisted of 612 males obtained from the UK GCA Consortium (UKGCA) (for further details, see supplement). Favourable ethical opinion was granted by the local Research Ethics Committee (05/ Q1108/28) and all participants provided informed written consent. A summary of the cohort can be found in Supplementary Table 3.
In total, 1650 (98.9%) of samples had a read depth > 100 and all 1667 (100%) had a read depth > 30. Despite the more stringent inclusion criteria, no mutations in GCA cases were found, suggesting VEXAS is rarely misdiagnosed as GCA in the UK. In contrast, seven individuals were identified with a UBA1 mutation (Table 2) in the cytopenic cohort (n = 7/1055, 0.66%). One case (P7) was subsequently found to have been reported in a previous study. All variants identified have been published as a cause of VEXAS and either lead to substitution of Met41 or affect the canonical splice acceptor site. On average, the variant allele frequency (VAF) of the mutation was 44.1% (range: 29.5-59.3%). All variants were confirmed by Sanger sequencing.
Six patients had an undiagnosed cytopenia with inflammatory complications, of which five had received steroid treatment and were responsive ( Table 2). No clinical information was available for the seventh patient (P5). Re-examination of available bone marrow confirmed the presence of vacuoles in promyelocytes. Importantly, these patients had all undergone invasive hematological investigations for unexplained cytopenia without a confirmed diagnosis. Of the seven cases, six of the patients were identified from the 595 male cytopenic cases (1.00%) and had clinical features consistent with previous VEXAS studies (male, over 55 years old with hematological and auto-inflammatory disease) [1]. The frequency of VEXAS in male patients with a confirmed myeloid malignancy has been previously reported by Zhao et al. screening 33 males with MDS/CMML for UBA1 by Sanger sequencing, finding 4 (12%) with mutations [2]. This study was however restricted to male patients and those with confirmed inflammatory/autoimmune disease. Altogether, we add to the growing number of male VEXAS cases with UBA1 mutations.
Interestingly, one patient (P2) with a UBA1 mutation was from the 460 cytopenic female cases (0.02%). Four female VEXAS cases have now been described, all subsequently found to have Monosomy X [1]. We performed a wholegenome SNP array on bone marrow DNA from the patient but found no evidence of X chromosome Monosomy or microdeletion around UBA1. As a SNP array is unable to detect deletions < 10 kb, we cannot rule out the presence of a smaller deletion encompassing UBA1. While one further possibility is that the wild-type allele is undergoing X-inactivation, leading to only the allele containing the somatic UBA1 being expressed, previous studies have shown UBA1 does not undergo X-inactivation [3]. Further work is therefore required to determine exactly why this female case has VEXAS.
When compared to male VEXAS patients, no difference in variant allele frequency was observed, and the VAF of P2 was 33%, within the range observed in the male cases (range: 19-52%) which may indicate the presence of an undetected micro-deletion. Hematologically, she had minimal dysplasia in her bone marrow cells, increased cellularity and vacuoles in promyelocytes, consistent with male VEXAS cases, and displayed similar inflammatory features including fevers and pulmonary infiltrates. To our knowledge, this is the first example of a female with VEXAS with comparable variant allele frequency to male VEXAS cases but with a normal SNP genotyping array result. This is the first study investigating the frequency of UBA1 mutations in patients with unexplained cytopenia. Retrospective analysis of all seven VEXAS patients in this study, for whom we had complete information, showed all but one had macrocytic anemia as part of their presentation. One VEXAS patient was anemic, but with normal MCV. No cases were found among patients with normal hemoglobin levels. If we had therefore restricted our analysis to patients with confirmed macrocytic anemia, the incidence of VEXAS would have been much higher in both males and females. Unfortunately, we did not have complete peripheral blood count parameters available for all patients to provide accurate figures. Therefore, based on our findings, not only should VEXAS be suspected in patients with unexplained macrocytic anemia, but it should also be considered in the absence of macrocytosis in patients with anemia and relevant inflammatory complications.
Prior to UBA1 screening, all cytopenia patients had undergone prior targeted genetic testing for 27 genes most commonly associated with myeloid malignancy as part of their usual clinical care. Two of the VEXAS cases had a variant in a second gene: P3 was found to harbour a lowfrequency ASXL1 null mutation (p.Tyr591Ter VAF 7%) and P5 was found to have a DNMT3A frameshift mutation (p.Lys721ArgfsTer58, VAF 55%) ( Table 2). No studies have yet reported UBA1 and ASXL1 variants in the same patient; however, somatic DNMT3A variants in VEXAS cases have been described [4]. Importantly, mutations in these genes, particularly in isolation, have been reported in aging healthy individuals and therefore could represent coincidental agerelated clonal hematopoiesis. Ultimately, the significance of these co-occurring variants in the same patient remains unknown.
Although GCA has been reported as part of inflammatory manifestations or mimic of VEXAS, we did not find any undiagnosed cases in our large cohort. A recent smaller study, which included 44 patients (15 male and 29 females), also found no undiagnosed cases of VEXAS in their cohort [5]. It is likely that in the absence of other cardinal features of VEXAS, such as MDS or macrocytic anemia, mutations in UBA1 are unlikely to be found in otherwise uncomplicated GCA. In summary, we describe a high-throughput screen for UBA1 exon 3 and identify seven cases of VEXAS syndrome in patients with unexplained cytopenia, including one female patient without Monosomy X. Screening for UBA1 mutations in patients with unexplained cytopenia should therefore be considered, particularly in those presenting with macrocytic anemia and inflammatory or autoimmune conditions. Our amplicon assay provides a highthroughput inexpensive method to screen large cohorts and inclusion of UBA1 in myeloid targeted sequencing panels should also be considered.